Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

NCT ID: NCT02918123

Last Updated: 2018-03-14

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 9 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-01-17
• Study Completion Date: 2021-12-31

Brief Summary

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Detailed Description

This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis.

Approximately 9~18 subjects will be administrated FURESTEM-CD Inj.

FURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.

Conditions

Psoriasis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

1. FURESTEM-CD Inj. 5.0x10^7 cells

2. FURESTEM-CD Inj. 1.0x10^7 cells

3. FURESTEM-CD Inj. 2.0x10^8 cells

Group Type: EXPERIMENTAL

FURESTEM-CD Inj.

Intervention Type: BIOLOGICAL

Patients will be treated FURESTEM-CD Inj. Subcutaneous injection

Interventions

FURESTEM-CD Inj.

Patients will be treated FURESTEM-CD Inj. Subcutaneous injection

Intervention Type: BIOLOGICAL

Other Intervention Names

hUCB-MSCs

Eligibility Criteria

Inclusion Criteria

1. 19-65 years old(both sexes)

2. Have been diagnosed with plaque-type psoriasis at least 6 months prior to screening (subjects with concurrent psoriatic arthritis[PsA] may be enrolled)

3. Psoriasis Area and Severity Index (PASI) score >= 12 at screening

4. BSA(Body Surface Area) >= 10 percentage at screening

5. Have had at least one of the following conventional systemic agent for the treatment of psoriasis,

• MTX, Cyclosporine, Photochemotherapy, TNF-alpha inhibitor or IL-12/IL-23 inhibitor

6. Subject who would agree to avoid prolonged sun exposure, use of tanning booths or other ultraviolet light sources during the clinical study

7. Subject who understands and voluntarily signs the informed consent form

Exclusion Criteria

1. Subject who has other types of psoriasis (eg. Erythrodermic, guttate, or pustular)

2. Have a history of chronic or recurrent infectious disease

3. Have received phototherapy or any systemic medications/treatments within 4 weeks of screening that could affect psoriasis or PASI evaluation

4. Have used topical medications/treatments within 2 weeks of screening that could affect psoriasis or PASI evaluation

5. Have used any systemic immunosuppressants within 4 weeks of screening

6. Have been administered with the following biological agents that could affect plaque-type psoriasis

• Etanercept - within 4 weeks of screening
• Adalimumab, alefacept, infliximab - within 2 months of screening
• Ustekinumab - within 4 weeks of screening
• Other investigational biological agents - within 4 weeks of screening/five half-lives(whichever was longer)

7. Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of childbearing potential must have a negative urine pregnancy test at screening)

8. Have been administered any types of investigational drugs within the previous 4 weeks or five half-lives of the investigational agent, whichever is longer

9. Subject who already took or need to take medicine which is prohibited during the clinical study

10. Subject who has sever dyshepatia (Creatinine value ≥ 2X Upper limit of the normal range at screening test)

11. Subject who has severe renal dysfunction (AST/ALT value ≥ 2X Upper limit of the normal range at screening test)

12. Have received a live viral or bacterial vaccination within 3 months of screening

13. Have had a BCG(Bacillus Calmette-Guérin) vaccination within 12 months of screening

14. Have a transplanted organ(with the exception of a corneal transplant > 3 months prior to screening)

15. Have any known malignancy or have a history of malignancy

16. Have a history of hypersensitivity, heavy metal poisoning etc. to drugs which are composed of similar components or have undergone allergy immunotherapy previously for prevention of anaphylactic reactions

17. Have had a serious infection (eg. Sepsis, pneumonia or pyelonephritis), or have been hospitalized or received IV antibiotics for an infection during the 2 months prior to screening

18. Positive for Hepatitis B virus(HBV) surface antigen or anti-Hepatitis C virus antibody screening

19. Known to have had a substance abuse(drug or alcohol) problem within 12 months of screening

20. Subject who experienced stem cell therapy

21. Any other conditions which the PI suspect the patient to be unsuitable for the clinical

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kang Stem Biotech Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Taeyoon Kim

Role: PRINCIPAL_INVESTIGATOR

Seoul St. Mary's Hospital

Locations

The Catholic Univ. Korea Seoul, St. Marry's Hospital

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Eunji Kang

Role: CONTACT

ejkang@kangstem.com

82-2-2036-7533

Facility Contacts

Tae-yoon Kim

Role: primary

Other Identifiers

KSB-PsO

Identifier Type: -

Identifier Source: org_study_id